<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Clin Trials</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Clin Trials</journal-id><journal-id journal-id-type="publisher-id">pctr</journal-id><journal-id journal-id-type="publisher-id">plct</journal-id><journal-id journal-id-type="pmc">plosclin</journal-id><journal-title-group><journal-title>PLoS Clinical Trials</journal-title></journal-title-group><issn pub-type="epub">1555-5887</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">1865088</article-id><article-id pub-id-type="doi">10.1371/journal.pctr.0020023</article-id><article-id pub-id-type="publisher-id">07-PLCT--00020</article-id><article-id pub-id-type="sici">plct-02-05-02</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Infectious Diseases</subject></subj-group></article-categories><title-group><article-title>Correction: A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK-Vanguard Study</article-title><alt-title alt-title-type="running-head">Correction</alt-title></title-group><pub-date pub-type="collection"><month>5</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>4</day><month>5</month><year>2007</year></pub-date><volume>2</volume><issue>5</issue><elocation-id>e23</elocation-id><permissions><copyright-statement>Copyright: © 2007 Public Library of Science.</copyright-statement><copyright-year>2007</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><related-article id="d35e66" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1371/journal.pctr.0010003" xlink:title="Research Article" vol="1" page="e3">
<article-title>A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK-Vanguard Study</article-title>
</related-article><counts><page-count count="1"></page-count></counts><custom-meta-group><custom-meta><meta-name>citation</meta-name><meta-value>(2007) Correction: A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard study. PLoS Clin Trials 2(5): e23. doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pctr.0020023">10.1371/journal.pctr.0020023</ext-link></meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="3078" xml_f="3081" txt_i="7" txt_f="10">In </offsets><italic><offsets xml_i="3089" xml_f="3110" txt_i="10" txt_f="31">PLoS Clinical Trials,</offsets></italic><offsets xml_i="3119" xml_f="3144" txt_i="31" txt_f="56"> volume 1, issue 1, doi: </offsets><ext-link ext-link-type="doi" xlink:href="10.1371/journal.pctr.0010003"><offsets xml_i="3216" xml_f="3244" txt_i="56" txt_f="84">10.1371/journal.pctr.0010003</offsets></ext-link><offsets xml_i="3255" xml_f="3256" txt_i="84" txt_f="85">:</offsets></p><p><offsets xml_i="3263" xml_f="3580" txt_i="86" txt_f="403">The following competing interest was declared by the author on submission, but due to an error the text was not included in the published version of the article: “Sean Emery receives research support from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Chiron, GlaxoSmithKline, Merck Sharpe and Dohme, and Roche.”</offsets></p></body></article>